Lung Based Engineered Micro-Pancreas Sustains Human Beta Cell Survival and Functionality

Abstract

The whole world has been affected by a dramatically increasing prevalence of diabetes. Today, the etiology of both type 1 and type 2 diabetes is thought to revolve around the dysfunction of β-cells, the insulin producing cells of the body. Within the pharmaceutical industry, the evaluation of new drugs for diabetes treatment is mostly done using cell lines or rodent islets and depends solely on the assessment of static insulin secretion. However, the use of cell lines or rodent islets is limiting lack of similarity of the human islet cells, leading to a constrain of the predictive value regarding the clinical potential of newly developed drugs. To overcome this issue, we developed an Engineered Micro-Pancreas as a unique platform for drug discovery. The Engineered Micro Pancreas is composed of (i) an organ-derived micro-scaffold, specifically a decellularized porcine lung-derived micro-scaffold and (ii) cadaveric islets seeded thereon. The Engineered Micro Pancreas remained viable and maintained insulin secretion in vitro for up to three months. The quantities of insulin were comparable to those secreted by freshly isolated human islets and therefore hold the potential for real-time and metabolic physiology mimicking drug screening.

Key words

human islets - engineered micro pancreas - drug development - scaffold - micro-organ-matrix

Publication History

Received: 01 October 2019

Accepted: 30 October 2019

Article published online:
11 December 2019

• References

• 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002–2030. PLoS Med 2006; 3: 2011-2030
• 2 Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229
• 3 Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: The last ten years. Cell 2012; 148: 1160-1171
• 4 Sionov RV, Finesilver G, Sapozhnikov L. et al. Beta cells secrete significant and regulated levels of insulin for long periods when seeded onto acellular micro-scaffolds. Tissue Eng Part A 2015; 21: 2691-2702
• 5 Abualhassan N, Sapozhnikov L, Pawlick RL. et al. Lung derived microscaffolds facilitate diabetes reversal after mouse and human intraperitoneal islet transplantation. PLoS One 2016; 11: 3156053
• 6 Ricordi C, Lacy PE, Finke EH. et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413-420
• 7 Kragl M, Lammert E. Basement membrane in pancreatic islet function. Adv Exp Med Bio 2010; 654: 217-234
• 8 Song JJ, Ott HC. Organ engineering based in decellularized matrix scaffolds. Trends Mol Med 2011; 17: 424-432
• 9 Giraldo JA, Weaver JD, Stabler CL. Enhancing clinical islet transplantation through tissue engineering strategies. J Diabetes Sci Techno 2010; 4: 1238-1247
• 10 Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: Relevance to scaffold design and transplantation. Cell Transplantation 2009; 18: 1-12
• 11 Cheng JY, Raghunath M, Whitelock J. et al. Matrix components and scaffolds for substained islet function. Tissue ENg Part B 2011; 17: 235-247
• 12 Huang G, Greenspan DS. ECM roles in the function of metabolic tissues. Trends Endocrinol Metab 2012; 23: 16-22
• 13 Brissova M, Fowler MJ, Nicholson WE. et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53: 1087-1097
• 14 Cabrera O, Berman DM, Kenyon NS. et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006; 103: 2334-2339
• 15 Braun M, Ramracheya R, Bengtsson M. et al. Voltage-gated ion channels in human pancreatic beta-cells: Electrophysiological characterization and role in insulin secretion. Diabetes 2008; 57: 1618-1628
• 16 Henquin JC, Dufrane D, Menquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes 2006; 55: 3470-3477
• 17 Rezania A, Bruin JE, Arora P. et al. Reversal of diabetes with insulin producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014; 32: 1121-1133
• 18 Pagliuca FW, Millman JR, Gurtler M. et al. Generation of functional human pancreatic B cells in vitro. Cell 2014; 159: 428-439